Trial Profile

Neoadjuvant Pembrolizumab and IO102-103 Prior to Curative-intent Surgical Care for Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 16 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Adjuvanted imsapepimut and etimupepimut (Primary) ; Pembrolizumab (Primary)
Indications Head and neck cancer; Squamous cell cancer
Focus Therapeutic Use
Acronyms KIEO

Most Recent Events

16 Nov 2023 Planned initiation date changed from 16 Oct 2023 to 1 Dec 2023.
12 Oct 2023 Planned End Date changed from 1 Sep 2028 to 16 Oct 2028.
12 Oct 2023 Planned primary completion date changed from 1 Sep 2026 to 16 Oct 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com